← Home
Risks
1. Dependence on Humira: Humira represents a large portion of AbbVie's revenue. If the drug loses patent exclusivity, AbbVie could suffer a significant drop in revenue.
2. Competition: There is increasing competition in the biopharmaceuticals space, which could limit AbbVie's opportunity for growth.
3. Regulatory Risk: AbbVie must comply with stringent global regulations in order to bring new drugs to market, or risk costly fines.
4. Acquisition Risk: Acquisitions are risky for any company, and AbbVie is no exception. Acquiring smaller companies or entering new markets could result in unforeseen costs or timing delays.